Lurasidone in the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo- and Olanzapine-Controlled Study

Abstract

Lurasidone was an effective treatment for patients with acute schizophrenia. Safety assessments indicated a higher frequency of adverse events associated with 120 mg/day of lurasidone compared with 40 mg/day.

New drugs: Lurasidone for schizophrenia

“…[1][2][3][4][5] However, efficacy was not consistently shown for each dose and a dose-response relationship was not evident in the trials. For example, in a study of lurasidone 40 mg, 80 mg and 120 mg, only the 80 mg dose had a statistically significant effect over placebo.…”

“…4 Discontinuation rates were very high in some of the trials (28-65%). [1][2][3][4][5] Lack of efficacy and withdrawal of consent were the most common reasons for stopping treatment.…”

“…[1][2][3][4][5] After six weeks of treatment, once-daily doses of 40 mg, 80 mg, 120 mg and 160 mg significantly lowered signs and symptoms of The most common adverse events in the short-term trials were somnolence (17% of patients), extrapyramidal symptoms (14%), akathisia (13%), insomnia (10%) and nausea (10%). Tachycardia, blurred vision, abdominal pain, diarrhoea, decreased appetite, rash, pruritus, hypertension and elevated creatine kinase also occurred in 1-10% of people.…”

Lurasidone is not associated with risk of QTc prolongation

“…1 Randomization was carried out via interactive voice response system in a 1:1:1:1 ratio for each of the treatment arms. Baseline characteristics, including symptom severity, age, sex, and race, were similar between all four groups.…”

Lurasidone for major depressive disorder with mixed features and irritability: a post-hoc analysis

“…Lurasidone has demonstrated efficacy in acute and long-term treatment of schizophrenia, [24][25][26] as well as in treatment of bipolar depression, both as monotherapy and as an adjunctive therapy with lithium or valproate. 27,28 The purpose of the present post-hoc analysis was to assess the efficacy of lurasidone in treating MDD patients with mixed features presenting with irritability.…”